BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33415559)

  • 1. Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease.
    Utuama O; Permuth JB; Dagne G; Sanchez-Anguiano A; Alman A; Kumar A; Denbo J; Kim R; Fleming JB; Anaya DA
    Ann Surg Oncol; 2021 Apr; 28(4):1939-1949. PubMed ID: 33415559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis.
    Yadav S; Xie H; Bin-Riaz I; Sharma P; Durani U; Goyal G; Borah B; Borad MJ; Smoot RL; Roberts LR; Go RS; McWilliams RR; Mahipal A
    Eur J Surg Oncol; 2019 Aug; 45(8):1432-1438. PubMed ID: 30914290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
    Yang Z; Jiang X
    BMC Gastroenterol; 2023 Apr; 23(1):122. PubMed ID: 37046191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma.
    Sutton TL; Billingsley KG; Walker BS; Enestvedt CK; Dewey EN; Orloff SL; Mayo SC
    Am J Surg; 2021 Jun; 221(6):1182-1187. PubMed ID: 33707077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Chemotherapy for Intrahepatic, Perihilar, and Distal Cholangiocarcinoma: a National Population-Based Comparative Cohort Study.
    Parente A; Kamarajah SK; Baia M; Tirotta F; Manzia TM; Hilal MA; Pawlik TM; White SA; Dahdaleh FS
    J Gastrointest Surg; 2023 Apr; 27(4):741-749. PubMed ID: 36749556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes?
    Ayabe RI; Paez-Arango N; Estrella JS; Newhook TE; Tzeng CD; Chun YS; Lee S; Javle M; Vauthey JN; Tran Cao HS
    HPB (Oxford); 2023 Apr; 25(4):472-480. PubMed ID: 36781357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma.
    Miura JT; Johnston FM; Tsai S; George B; Thomas J; Eastwood D; Banerjee A; Christians KK; Turaga KK; Pawlik TM; Clark Gamblin T
    Ann Surg Oncol; 2015 Oct; 22(11):3716-23. PubMed ID: 25777092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Liver Metastases from Colorectal Cancer: a Multicenter, Propensity Score-Matched Cohort Study.
    Hirokawa F; Ueno M; Nakai T; Kaibori M; Nomi T; Iida H; Tanaka S; Komeda K; Hayami S; Kosaka H; Hokuto D; Kubo S; Uchiyama K
    J Gastrointest Surg; 2022 Apr; 26(4):772-781. PubMed ID: 34664190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
    Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
    [No Abstract]   [Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy versus upfront surgery as the initial treatment for patients with resectable, synchronous colorectal cancer liver metastases.
    Lee JM; Han YD; Cho MS; Hur H; Lee KY; Kim NK; Min BS
    J Surg Oncol; 2023 Sep; 128(4):549-559. PubMed ID: 37288777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience.
    Mason MC; Massarweh NN; Tzeng CD; Chiang YJ; Chun YS; Aloia TA; Javle M; Vauthey JN; Tran Cao HS
    Ann Surg Oncol; 2021 Oct; 28(11):6725-6735. PubMed ID: 33586068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma.
    Riby D; Mazzotta AD; Bergeat D; Verdure L; Sulpice L; Bourien H; Lièvre A; Rolland Y; Garin E; Boudjema K; Edeline J
    Ann Surg Oncol; 2020 Oct; 27(10):3729-3737. PubMed ID: 32472411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Staging Concordance and Downstaging After Neoadjuvant Therapy on Survival Following Resection of Intrahepatic Cholangiocarcinoma: A Bayesian Analysis.
    Alaimo L; Moazzam Z; Lima HA; Endo Y; Woldesenbet S; Ejaz A; Cloyd J; Guglielmi A; Ruzzenente A; Pawlik TM
    Ann Surg Oncol; 2023 Aug; 30(8):4799-4808. PubMed ID: 37029867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study.
    Wang L; Deng M; Ke Q; Lou J; Zheng S; Bi X; Wang J; Guo W; Li F; Wang J; Zheng Y; Li J; Cheng S; Zhou W; Zeng Y
    Cancer Med; 2020 Apr; 9(8):2674-2685. PubMed ID: 32072774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Chemotherapy Benefits Survival in High-Grade Upper Tract Urothelial Carcinoma: A Propensity Score-Based Analysis.
    Chen L; Ou Z; Wang R; Zhang M; He W; Zhang J; Zu X; Yi L; Xu R; Jiang S; Qi L; Wang L
    Ann Surg Oncol; 2020 Apr; 27(4):1297-1303. PubMed ID: 31853757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis.
    Hester C; Nassour I; Adams-Huet B; Augustine M; Choti MA; Minter RM; Mansour JC; Polanco PM; Porembka MR; Wang SC; Yopp AC
    J Gastrointest Surg; 2018 Dec; 22(12):2080-2087. PubMed ID: 30030718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of neoadjuvant chemotherapy based on our resectability criteria for locally advanced perihilar cholangiocarcinoma.
    Gyoten K; Kuriyama N; Maeda K; Ito T; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Kishiwada M; Mizuno S
    Langenbecks Arch Surg; 2023 Jul; 408(1):261. PubMed ID: 37392289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is it safe to administer neoadjuvant chemotherapy to patients undergoing hepatectomy for intrahepatic cholangiocarcinoma? ACS-NSQIP propensity-matched analysis.
    Choi WJ; Ivanics T; Claasen MPAW; Gallinger S; Hansen B; Sapisochin G
    HPB (Oxford); 2022 Sep; 24(9):1535-1542. PubMed ID: 35474005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
    de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
    Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.